Price History

Hover for the daily close. The dotted line marks the period open.

Compare ODTX with… →

ODTX Key Statistics

As of Sep 4, 2026

Trading

Open: $26.24
Previous Close: $26.40
Day's Range: 25.71–29.05
52-Week Range: 15.10–29.05
Volume: 269.00K

Valuation

Market Cap: $1.38B
P/E Ratio: unprofitable
EPS (ttm): −3.34

Financials (FY)

Revenue (FY): $2.98M−33.45%
Net Income (FY): −$148.65M
Profit margin: 0.00%
Shares Outstanding: 48.06M

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 260.95K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ODTX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$2.98M	−$148.65M	−4994.9%
2024	$4.47M	−$129.32M	−2891.8%
2023	$1.04M	−$125.94M	−12144.5%
2022	$0.00	−$124.67M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$2.98M	—	−$161.16M	−$148.65M	−4994.9%
2024	$4.47M	—	−$135.22M	−$129.32M	−2891.8%
2023	$1.04M	—	−$133.44M	−$125.94M	−12144.5%
2022	$0.00	—	−$122.78M	−$124.67M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ODTX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	ODTX	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Odyssey Therapeutics, Inc. (ODTX) at $1.38B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 100.

Over the past 52 weeks the price has ranged from $15.10 to $29.05. The most recent close on file for ODTX is $28.76, dated September 4, 2026. That is +$2.36 (+8.94%) against the previous close. The latest close sits 90.46% above that 52-week low.

Financial Health

In fiscal 2025, Odyssey Therapeutics, Inc. reported revenue of $2.98M. Against the prior fiscal year total of $4.47M, that is a change of −33.45%. The same year closed with a net loss of $148.65M. Profit margin runs at 0%. Trailing earnings per share are −3.34.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $2.98M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Growth & Income

The record shows no dividend for ODTX.

So far in 2026 the price is +75.15%.

Peer Comparison

Odyssey Therapeutics, Inc. (ODTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Odyssey Therapeutics, Inc.	ODTX	$1.38B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Odyssey Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.

Visit website →

Odyssey Therapeutics, Inc. (ODTX) Stock Analysis